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The 59 cases, 46 paralytic reported for the two-week period which 
ended September 15, 1962, are in marked contrast to the 163 cases, 100 
paralytic, reported during the comparable two weeks in 1961.
During the two-^week period 22 States reported cases. There were no 
new epidemic concentrations. In Section 2, a further description is pro­
vided of the poliovirus outbreak noted in Pasadena (Los Angeles County), 
California, (see PSU No. 267, September 7, 1962). Also included is a report 
of cases of poliomyelitis among oral polio vaccinees in Nebraska.
Sections 3 and 4 contain summaries of paralytic cases occurring 
during 1962 submitted on individual case forms and cases occurring within 
30 days of vaccination.
Appended is a special report by the Surgeon General to the Medical 
Profession on nThe Association of Cases of Poliomyelitis with the Use of 
Type III Oral Poliomyelitis Vaccines.”
1. CURRENT POLIOMYELITIS MORBIDITY TRENDS
Fifty-nine cases of poliomyelitis, 46 paralytic, were reported during 
the two-week period ending September 15. The current week ending September 
15 accounted for 29 cases, 21 paralytic, compared with 30 cases including 
25 paralytic for the previous week. A total of 163 cases, 100 paralytic, 
was reported for the same two-week period in 1961.
Twenty-two States reported poliomyelitis during the current two- 
week period. Texas accounted for the largest number with 10 cases, 7 of 
which were paralytic. California reported 7 paralytic cases. A special 
report concerning the case concentration in this State is presented in 
Section 2. Of the remaining 20 States, four reported 4 cases each.
The following tables, which give the total cumulative and six-week 
incidence through the 37th week for 1962 and for the preceding 4 years, 
show that this yearts totals are much reduced from the 1961 figures.
Polio (Cumulated Weekly) Through the 37th Week for Past Five Years
1962 1961 1960 1959 1958
Paralytic 414 517 1312 3455 1461
3000Total 529 780 1908 5474
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Six-Week Totals (32nd thru 37th Week) for Past Five Years
1962 1961 1960 1959 1958
Paralytic 159 278 632 1855 839
Total 195 418 960 3023 1746
2. STATE REPORTS
A. California
Of the 7 cases of poliomyelitis reported by Dr. Henry Renteln, Chief 
of the Surveillance Section, California State Health Department during the 
past two weeks, 6 were from Los Angeles County, with 3 from the City of 
Pasadena which is within the county. Type I oral polio vaccine was ad­
ministered in a mass campaign as an epidemic deterrent in the epidemiolo- 
gically relevant area in Pasadena on September 9 and the days following. 
(See PSU #267, September 7, 1962). All of the cases reported during the 
past two weeks from Pasadena occurred before vaccine administration.
A total of 8 cases has occurred in Pasadena in 1962. Six of the 8 
had onsets of illness in August. Six type I poliovirus isolates have been 
recovered from these. All of the poliomyelitis reported from this city 
occurred in a lower socio-economic area of Pasadena, and the patients in­
volved have all been Negro. All but two were in the pre-school age group. 
None had received adequate inactivated polio vaccine immunizations.
To study polio and enterovirus prevalence and the subsequent effect 
of the vaccine virus, a sampling of 208 rectal swabs was obtained from 
children in individual households in that area prior to vaccination.
Samples from these children will be obtained on two further occasions in 
a longitudinal study.
B. Nebraska
Dr. E.A. Rogers, Director, Communicable Disease Control, has reported 
that four cases of poliomyelitis have been observed in this State in 1962. 
All 4 patients had participated in mass oral polio vaccine immunization 
campaigns in the State. Epidemiological and clinical data were available 
on the first 3 of the 4 cases on September 15, 1962, and were included 
in the group considered by the Surgeon General’s special advisory committee 
(See Appended Report).
A line listing of the 4 cases appears below; they will be listed 
again in Section 4 at a later date.
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Doses
£ase_J .Age Race s § £ .IPV
Nebr-1 18 W F 5
Nebr-2 51 W M 0
Nebr-3 37 W M 0
Nebr-4 48 w F 0
Interval from 
OPV (days)
Onset Type I Type II Type
7/1 34 — 7
7/16 51 — 22
7/23 43 — 15







3. 1962 PARALYTIC CASES REPORTED TO PSU
Of the 414 cases of paralytic poliomyelitis reported through the 
week ending September 15, 393 had onset in 1962. The Polioniyelitis 
Surveillance Unit has received individual case forms on 318 of the 393 
paralytic cases. The vaccination status of the 318 paralytic cases by 
age group is shown below.
Paralytic Poliomyelitis by Age Group 
And Vaccination History Reported on PSU Forms 
(Through September 21, 1962)
Age Doses of Inactivated Vaccine
Group ov 1-2V 3V 4+V Unk Total Percent
0-4 108 30 6 8 8 160 50.3
5-9 31 8 8 15 3 65 20.4
10-14 15 4 8 4 1 32 10.1
15-19 8 2 4 0 0 14 4.4
20-29 15 5 1 3 3 27 8.5
30-39 6 2 0 2 1 11 3.5
40+ 7 1 0 0 1 9 2.8
TOTAL 190 52 27 32 17 318 100.0
PERCENT
DOSES ' 63.1 17.3 9.0 10.6 - 100.0
Of the 152 cases with known vaccination history in the 0-4 age group, 
108 (71.1 percent) had not received any poliomyelitis vaccinations.
To date in 1962, the Poliomyelitis Surveillance Unit has received 
results of virological studies on 144 of the 318 paralytic cases. Polio­
virus isolations have been reported on 119 (82.6 percent) of the 144 cases. 
Of these, 100 are Type I and 19 are Type III poliovirus. Isolates have 
been reported from the following States.
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Poliovirus
State I II III Total
Alabama 2 0 0 2
Arizona 2 0 0 2
California 4 0 2 6
Colorado 1 0 0 1
Georgia 1 0 1 2
Illinois 8 0 2 10
Kentucky 8 0 1 9
Louisiana 3 0 0 3
Massachusetts 2 0 0 2
Michigan 0 0 1 1
Minnesota 4 0 0 4
Mississippi 0 0 1 1
Montana 1 0 0 1
New York 4 0 2 6
Ohio 4 0 4 8
Oregon 0 0 3 3OPennsylvania 3 u 0 J
Tennessee 1 0 0 1
Texas 49 0 2 51
Utah 1 0 0 1
West Virginia 1 0 0 1
Wyoming 1 0 0 1
TOTAL 100 0 19 119
4. ROUTINE POLIOMYELITIS SURVEILLANCE - 1962
A. Cases with Onset Within 30 Days of Vaccine (Inactivated)
During the two-week period ending September 15, there have been 
no cases of poliomyelitis within 30 days following vaccination with 
inactivated vaccine reported to the Poliomyelitis Surveillance Unit.
The total remains at 11 under-30-day cases reported, including 
8 paralytic. Eight of the cases have occurred in Texas; Alabama reported 
two cases, and Pennsylvania one case. None of the sites of inoculations 
correlated with the sites of first paralysis.
B. Cases with Onset Within 30 Days of Vaccine (Oral)
Four cases of poliomyelitis, 2 paralytic, occurring within 30 days 
following oral vaccine feeding were reported to the Poliomyelitis Surveillance
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Unit during the past two weeks. Pennsylvania and Tennessee reported one 
case each and Texas accounted for two cases. All four cases had been fed 
Type I oral polio vaccine. The cases from Texas and Pennsylvania received 
the vaccine in communities where the oral polio vaccine was used as an 
epidemic deterrent. A detailed listing of these cases is presented below.









Penna. Cambria 8 F 8-22 8-18 I 4 days NP
Tenn. Gibson 25 H 8-30 8-20 I 10 days P
Texas Harris 50 M 7-26 7-22 I 4 days NP
Texas Harris 45 M 8-16 7-22 I 25 days P
\
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Figure 1 C U R R E N T  U. S. P O L IO  IN C ID E N C E
C O M P A R E D  W IT H  Y E A R S  I9 5 T ,  1 9 5 9  and 1961 
A p ril -  D ecem ber, by week
Data Provided by National Office of Vital Statistics and Communicable Disease Center
Table 1











Region 1962 8/11 8/18 8/25 9/1 9/8 9/15 Total 1961 1960 1923-
UNITED STATES
Paralytic 414 22 22 38 31 25 21 159 278 632 1855
Nonparalytic 82 9 2 5 6 4 4 30 101 217 927
Unspecified 33 - - 1 - 1 4 6 39 111 241
Total 529 31 24 44 37 30 29 195 418 960 3023
NEW ENGLAND
Paralytic 6 - — - — - - — 12 48 ioy
Total 6 — — — — — — — 16 72 159
Maine — - - - — — — - 2 15 13
New Hampshire - - - - - - - - 1 - 3
Vermont - — - - - - - — 3 5 X
Massachusetts 4 - - - - - - - 7 16 80
Rhode Island - — — — — - - — - 18 l
Connecticut 2 - - - - - - - 3 18 60
MIDDLE ATLANTIC
Paralytic 39 1 1 6 1 4 2 15 101 126 150 2 86Total 56 2 1 8 1 5 2 19 151 165
New York 44 2 1 2 1 1 2 9 120 84 17159
56New Jersey 4 -
- 2 - - - 2 14 41
Pennsylvania 8 — - 4 - 4 - 8 17 40
EAST NORIH CENTRAL
Paralytic 38 5 1 3 8 4 1 22 31 112 202543
104
56
Total 54 5 1 3 9 6 4 28 53 193
Ohio 16 — — 1 3 2 2 8 9 43
Indiana 7 1 - — — 2 — 3 6 50
Illinois 21 1 1 2 5 1 1 11 11 63 136231
16Michigan 7 3 - - 1 - 1 5 15 26Wisconsin 3 - - - - 1 — 1 12 11
WEST NORTH CENTRAL
Paralytic 16 2 2 4 8 10 26 310588
106Total 26 — 2 1 4 — 4 11 21 55Minnesota 6 — 2 — 1 - - 3 2 13
Iowa 5 — — — — — — - 10 5 160175Missouri 7 — — — 2 — - 2 3 10
North Dakota 3 - — 1 — - 1 2 6 yej
South Dakota 1 — — — — — 1 1 1 2 7










Segion 1962 8/11 8/18 8/25 9/l 9/8 9/15 Total 1961 1960 1959
SOUTH ATLANTIC
Paralytic 31 4 3 3 3 2 1 16 54 115 362
Total 35 5 3 3 3 2 1 17 69 154 464
Delaware — — — •M 3
Maryland — — — — — — — — 14 32 14
D.C. 2 — — — — — 1 1 — — 6
Virginia 8 3 - 1 1 - - 5 7 12 126
West Virginia 5 - - - 1 1 - 2 11 16 91
North Carolina 4 - - 1 - 1 - 2 6 32 90
South Carolina 4 - 2 - 1 - - 3 8 43 33
Georgia 6 2 1 1 - — — 4 8 9 65
Florida 6 - - - - - - - 15 10 36
EAST SOUTH CENTRAL
Paralytic 34 1 1 10 5 4 1 22 19 24 229
Total 44 1 1 11 5 4 4 26 26 77 326
Kentucky 17 — - 6 1 1 — 8 3 48 19
Tennessee 10 1 — 1 - 1 3 6 7 17 172
Alabama 14 — — 4 4 2 1 11 4 3 104
Mississippi 3 - 1 - - - - 1 12 9 31
West south central
Paralytic 188 10 11 11 7 9 6 54 24 37 210
Total 238 17 13 12 10 11 7 70 47 61 314
Arkansas 6 1 1 - 1 - 1 4 9 10 101
Louisiana 14 — 1 — - 3 — 4 20 2 39
Oklahoma 11 — 2 1 1 2 2 8 1 4 46
Texas 207 16 9 11 8 6 4 54 17 45 128
Mountain
Paralytic 8 - - - - - - - 4 7 33
Total 12 — — 1 — — 1 2 8 25 61
Montana 3 — — — — — — — — 1 3
Idaho 2 — 1 1 4 1 —
Wyoming 2 — — — — — 1 1 — 14 -
Colorado 1 — - - - - — - 3 5 11
New Mexico — _ — — — _ — — 2 12
Arizona 3 _ — — PM — 1 27
Utah 1 — 1 1 6
Nevada - - - - -  - - - - - 2
pacific
Paralytic 54 1 3 5 5 2 6 22 23 137 244
Total 58 1 3 5 5 2 6 22 27 158 282
Washington 2 — 1 — — — 1 2 7 12 84
Oregon 5 — — - — — — — 4 7 67
Oalifornia 50 1 2 5 5 2 5 20 15 137 126
Alaska ... _  _ — — _ 5
Nawaii 1 - - - - - - - 1 2 -
territory
Puerto Rico 10 — 1 — - ~ - 1 1 71 -
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With the Use of Type III Oral Poliomyelitis Vaccines
1A Technical Report 
by
Luther L. Terry, M. D.
Surgeon General, Public Health Service 
U. S. Department of Health, Education, and Welfare 
September 20, 1962
cio
1. The data in this report have been compiled by the Poliomyelitis 
Surveillance Unit, Communicable Disease Center, Public Health 
Service, U.S. Department of Health, Education, and Welfare. The 
information is based on routine morbidity and special polio­
myelitis surveillance reports, individual case investigations 
and a wide variety of laboratory and field studies, all of which 
represent the work of several hundred practicing physicians, 
local, state and federal health officials, epidemiologists, and 
laboratory scientists. Their contribution is gratefully 
acknowledged.
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On September 15, 1962, the Surgeon General *s Oral Poliomyelitis
3X3iiXavrnoiXr^ lo  10 noi.?sxoo3i&A orfT
Vaccine Advisory Committee met in Washington, D* C, and reviewed the 
a-^oosV  s m io x a o ilo 'I  -  I II  sq-;? CSU oiU 
data concerning the occurrence of cases of poliomyelitis after the
it? A
administration of oral poliomyelitis vaccines during the current
f* M -J
calendar year. After a full discussion of the problem the Committee
e-nrtlsV/ bus tnoi.tnoah3 .Arisen io w  .3  .U
unanimously recommended that the use of Type III vaccine be limited to
pre-school and school age children and to adults at high risk, i.e. those 
travelling to hyperendemic areas and those living in areas where Type III 
epidemics were present or impending. They advised that mass programs 
using Types I and II oral vaccines be continued for all age groups.*
The present report summarizes the information which was reviewed 
by the Committee and upon which its recommendations were based. Included 
are: 1) a brief review of the use of poliomyelitis vaccines in the
United States, particularly the use of the recently licensed oral polio­
myelitis vaccines; 2) an appraisal of the present poliomyelitis problem; 
and 3) a listing, in detail, of the cases of poliomyelitis that have 
occurred in association with the use of oral poliomyelitis vaccines.
r yd holsq jm o (ii> i  T'xoqai zxru ax sjbd
* The members of the Special Oral Poliomyelitis Vaccine Advisory 
Committee who approved the recommendations are: Drs. David
Bodian, John P. Fox, Archie L. Gray, William McD. Hammon, Hugh 
H. Hussey, Alexander D. Langmuir, Roderick Murray, John R. Paul, 
Edward B. Shaw, Joseph E. Smadel. Dr. Albert B. Sabin, also a 
member of the Committee, participated in its first two meetings 
on August 9 and 16, 1962. He was out of the country on September 
15 and was thus unable to be present at the meeting on that date. 
The Surgeon General served as Chairman of the Committee.
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This information is being made broadly available to the medical and 
health professions at this time in order that they may have the oppor­
tunity for a full understanding of the basis for the recommendations.
Use of Poliomyelitis Vaccines:
The Type I oral vaccine was licensed for distribution in inter­
state commerce on August 17, 1961; Type II vaccine on October 10, 1961; 
and Type III on March 27, 1962. Prior to these dates, experimental 
lots of the respective vaccines were employed in a number of small scale 
and some large scale community programs.
Since vaccine licensure, a great many community-wide vaccination 
programs have been carried out. The programs have ranged in size from 
those involving single small towns, to those which include metropolitan 
areas in several contiguous counties, to an essentially state-wide 
program in Massachusetts. The oral vaccines have also been employed 
for smaller programs among selected population groups and for routine 
use in private practice and health department immunization clinics.
In epidemic control, Type I vaccine was used immediately following 
release in the Syracuse, New York area and, in 1962, in many counties 
of Texas; in Mobile, Alabama; Pasadena, California; and several rural 
counties in Kentucky and Pennsylvania to abort existent or impending 
epidemics. Experimental lots of Type III vaccine were used in 1961 in 
outbreaks in Atlanta, Georgia, and in Newberry County, South Carolina. 
Commercial Type III vaccine was used in Washington County, Virginia,
in 1962.
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The estimated use of oral vaccines in the United States is 
summarized in Table 1. Utilization of both experimental lots and the 
licensed product is shown. Since it was recommended that Type I 
vaccine be fed first and because many programs did not start until 
late spring, the estimates show a much greater use of this type of 
vaccine than Types II and III, Estimated use in community programs of 
the 3 types of vaccine by month is shown in Figure 1.
In most areas the vaccine was offered to persons of all ages and 
found wide acceptance among adults as well as children. In a few areas, 
as in Massachusetts, use of the oral vaccines in public programs was 
largely limited to children.
During the past twelve months, the inactivated (Salk) poliomyelitis 
vaccines (IPV) have continued to be used although less widely. Since 
April 1955, a total of 537 million doses of IPV has been distributed.
A random sample survey of the population in September 1961 indicated 
that slightly more than 50,000,000 persons in the population had 
received 4 or more doses of the inactivated vaccine.
Incidence of Poliomyelitis:
The annual incidence of reported cases of poliomyelitis by 
paralytic status from 1955 through 1961 is shown in Table 2. The 
marked decline in paralytic cases can be attributed largely to the wide­
spread use of the inactivated polio vaccine. During the first 9 
months of 1962, the incidence of ̂poliomyelitis has further declined
as shewn in Table 3.
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Present data indicate that for 1962, the paralytic poliomyelitis 
rate for those under 20 will be approximately 7.6 per million; for those 
over 20, about 0.9 per million. These rates will represent a record 
low for the 52 year period since the reporting began.
The further decline in the incidence of poliomyelitis in 1962 may 
be attributed to the steadily improved immunization status of the 
population resulting both from the continued use of inactivated polio 
vaccine and the wide use of oral vaccines.
The Occurrence of Cases Following Oral Vaccine:
With the licensing of Type I oral vaccine in August 1961, the 
poliomyelitis surveillance program of the Communicable Disease Center 
placed particular stress on the evaluation of reported cases of polio­
myelitis developing after vaccine use. It was recognized that when 
millions of persons participate in an immunization program, any of a 
variety of subsequent events might occur coincidentally but be attributed 
erroneously to the vaccine. This could be particularly true of an inter­
current disease such as aseptic meningitis that might simulate polio­
myelitis and even poliomyelitis due to infection with wild polio­
viruses that had been acquired prior to the vaccination. The problem 
is compounded during the summer and early fall when many enteroviruses 
are actively circulating.
In epidemic control a number of cases of disease among vaccinees 
can be expected in the days immediately following an immunization program 
before there has been opportunity for immunity to develop. In non- 
epidemi areas, the frequency of coincidental cases should be lower,
although not necessarily zero. If vaccine is related in a causal way 
to the cases, the intervals between immunization and onset of disease 
should group within the expected 7 to 30 day incubation period of the 
disease.
Since August 17, 1961, when Type I oral vaccine became commercially 
available, there have been 62 cases of poliomyelitis officially reported 
to the Public Health Service in which oral polio vaccine had been 
administered within 30 days prior to the onset of symptoms.
During the epidemic in New York State in 1961, a total of 32 "under 
30-day vaccinated cases” was reported. Most of these developed soon 
after administration of the vaccine, in fact, 15 within 6 days. The 
early appearance of these cases indicates a coincidental rather than a 
causal relationship to vaccination. Similarly, in South Carolina,
Georgia, and Texas, a total of 17 "under 30-day vaccinated cases" was 
reported. Again, most appeared soon after vaccination, 11 within 6 
days, and do not suggest a causal relationship.
In the non-epidemic areas, a total of 16 "under 30-day vaccinated 
cases" has been reported. These have come from 7 states. Two followed 
Type I vaccine, one followed Type II vaccine, and 13 followed Type III 
vaccine. Eleven of the 16 occurred between the 15th and 29th day. This 
finding warranted further consideration of the possibility of a causal 
relationship to the vaccine, particularly to the Type III vaccine.
The Advisory Committee directed special attention to these 16 
under 30-day cases reported from non-epidemic areas. All available 
cOinical,,. epidemiological, -and. laboratory information was reviewed.
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Each case was considered individually, and excluded or not excluded 
by group decision from further consideration as to the possibility of 
its being vaccine induced. No case was excluded except by unanimous 
agreement of the consnittee members. Included for consideration were 
those cases clinically compatible with poliomyelitis which demonstrated 
any significant paralysis and in which laboratory findings to date were 
not inconsistent with a vaccine relationship. Descriptive data regard­
ing these cases are summarized in Table IV.
Of the two* cases of poliomyelitis reported following Type I vaccine 
administration, only one (case 2) was thought by the Committee to be 
entirely compatible clinically with polionyelitis. Of recent onset, the 
virologic studies on this patient are still in process. The clinical 
history of the other case (case 1) indicated it to be exceedingly mild 
and atypical. The patient experienced no known febrile illness, he was 
not hospitalized, and no cerebrospinal fluid studies were performed. He 
recovered with no residual paralysis.
The single case reported following immunization with Type II 
vaccine was found to have a Type III virus in his stool. Since Type III 
vaccine had not been fed, it can be concluded that the infection was 
due to a wild virus.
Eleven of the thirteen cases following Type III oral polio vaccine 
were considered by the Committee as possibly vaccine related. Of the 
two cases excluded, one (case 14) had an illness atypical for polio­
myelitis with no functional impairment after 30 days. Both Type I and
8
Type III polioviruses were recovered from the stool, 55 and 27 days 
respectively after Types I and III vaccines had been fed to the child.
The Type I virus which was recovered was characterized as "wild-like1* 
according to the results obtained by the modified Wecker and McBride 
tests. These tests are used to demonstrate slight antigenic differences 
between poliovirus strains of the same type. Since the virus strains 
may, after a period of intestinal multiplication, show such a shift in 
the antigenic characteristics of the viruses, no definitive interpretation 
of this finding was possible. The second case (case 16) which was 
excluded from further consideration had an insignificant paralytic residual 
and no detectable Type III antibody in either acute or convalescent 
serum specimens.
From 6 of the 11 cases, Type III poliovirus was recovered from 
stool specimens. Four of the six were characterized as "vaccine-like" 
by the modified Wecker and McBride tests. Although this finding was of 
interest, it unfortunately provided little help in determining whether 
the vaccine played a causal role. Each of these considered had been fed 
oral vaccine and, hence, might be expected to be excreting the Type III 
vaccine virus which might appear by the modified Wecker and McBride tests 
to be, as noted above, wither "wild-like" or "vaccine-like". Further, 
it is possible that the oral vaccine strain may have displaced a **wild" 
enterovirus which was, in fact, the etiological agent responsible for the 
paralytic illness. In summary, isolation of a Type III virus from the 
stool and demonstration of Type III antibodies in the patient*s sera 
sei'ved to indicate only that the paralytic disease would not be in­
compatible with Type III vaccine-induced disease.
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The eleven cases considered as possibly related to Type III 
vaccine feeding are between 16 and 52 years of age, with all but three 
of the cases over 30. The vaccine administered to this group of cases 
was from several lots and was not produced by any single manufacturer.
Of the 11 cases, 3 occurred in Oregon, 3 in Nebraska, 2 in Michigan,
2 in Ohio, and one in New York State. The clinical illnesses in these 
patients range from significant to severe. No deaths occurred. Among 
the eleven cases, the entire spectrum of non-fatal paralytic illness 
characteristic of poliomyelitis was evident.
Discussion Summary:
Of the reported cases to date, one following Type I vaccine and 
eleven following Type III vaccine were considered by the Committee to 
be clinically consistent with paralytic poliomyelitis and with laboratory 
findings which could not exclude a possible relationship to the adminis­
tration of oral vaccine.
As noted, a single case occurred within 30 days of Type I vaccine 
administration during a period of almost 9 months when approximately 
20,000,000 persons were fed Type I vaccine. This is wholly compatible 
with coincidental origin.
The 11 cases following Type III vaccine cannot all be assumed to 
be coincidental. The adult age distribution ranging from 16 to 52 
years with 8 of the cases over 30 years of age, and the clustering of 
the intervals from vaccine feeding to onset in the 2-3 week period 
suggest a vaccine relationship. For these reasons the Committee con­
cluded that "there is sufficient epidemiological evidence to indicate
that at least some of these cases have been caused by the Type III 
vaccines.”
The incidence, assuming all cases to have been vaccine induced, 
is but 11 cases among more than 13 million fed. This is less than one 
case per million doses given. When the risk is related to age it is 
apparent that adults are exposed to a greater hazard than are children. 
Inadequate information on the age specific vaccine acceptance rate, 
however, makes it impossible to calculate a more precise estimate of 
the risk at this time.
With the incidence of poliomyelitis at a low level in this 
country, the Committee therefore recommended that the Type III vaccine 
be restricted to pre-school and school age children and to those adults 
in high risk groups, such as those travelling to hyperendemic areas 
or in areas where a Type III epidemic is present or impending.
Since the vast majority of poliomyelitis cases occur among young 
children and since children are the principal disseminators of the 
virus, continued intensive immunization programs among this group are 
clearly indicated. If this group can be adequately immunized, the 




Estimated Use of Oral Poliomyelitis Vaccine (Sabin strains) in
the United States
Type of Vaccine (in 1000Ts of doses)
Experimental Vaccines
I II III Total







Community Prophylactic Programs 12,392 3,622 9,492 25,506
Epidemic Control 3,064 - 2 3,066
Other Programs, Routine Immuni­
zation Clinics and Private 
Practice
5,000 3,000 4,000 12,000
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Annual Incidence of Reported Cases of Poliomyelitis 
by Paralytic Status in the United States 
1955-1961
Table II
Number of Reported Cases
Year Paralytic Non-Paralytic Unspecified Total
1955 13,850 12,453 2,682 28,985
1956 7,911 6,555 674 15,140
1957 2,499 2,826 160 5,485
1958 3,697 1,941 149 5,787
1959 6,289 2,045 91 8,425
1960 2,v 25 626 39 3,190
1961 988 305 19 1,312
Table III
. r» . 4 _  O  i w  . .  * i i ^  **^ | c j h
■fr r>» £ ^  j
Incidence of Poliomyelitis by Paralytic Status in the United States
January thru 36th Week - 1962 and Comparable Periods in Previous Years
Paralytic Status 1962 1961 1960 1959
Paralytic 393 454 1,200 3,122
Non-Paralytic 78 151 363 1,394
Unspecified 29 77 167 4^0
TOTAL 500 682 1,735 4,956
Table IV
Cases of Reported Paralytic Poliomyelitis Occurring Within 30 Days of the 
Administration of Oral Poliomyelitis Vaccines in Non-Epidemic Areas
January 1 to September 15, 1962
Type I Vaccine
Onset Virus
Doses First Clinical Interval from OPV (days) Isolates Antibody Committee1
Case # Age Race Sex IPV Symptom Severity Type I Type II Type III Type Character Response Appraisal
1 3 W M 2 5/29 1 23 — — I Void Like I Excluded
2 25 W M 1 8/30 3 10 — — ** •a* Compatible
Type II Vaccine
3 2 W F 2 2/23 3 Over 90 8 — III - - Excluded
4
Type III Vaccine
4 23 W M 4 7/16 3 76 —— 17 III Wild Like Ill Compatible
5 36 W F 0 7/20 3 — — 22 III Vaccine Like III Coif:/: table
6 18 w F 5 7/1 3 34 — 7 III *# ** Compatible
7 51 w M 0 7/16 3 51 — 22 0 - Compatible
8 37 w M 0 7/23 3 43 — 15 - - - Compatible
9 49 w M 0 6/18 4 +90 — 26 0 II&III Compatible
10 16 w M 0 6/8 3 43 — 15 - - - Compatible
11 36 w M 0 7/15 4 — — 21 0 I &III Compatible
12 48 w F 0 5/5 4 34 — 7 III Vaccine Like Ill Compatible
13 39 w M 0 5/21 4 50 — 23 III Vaccine Like - Compatible
14 6 w M 0 5/25 1 54 — 27 I Wild Like - Excluded
o  F III Vaccine Like
15 52 Y i M 0 6/26 4 52 — 19 III Vaccine Like Ill Compatible
16 6 W M 4 6/12 2 37 — 5 I * * I Excluded
(SEE FOEUCWING PA.GF. FOR FOOTNOTES)
Footnotes for Table IV
Key for Severity: 1 - Complete Recovery, no residual paralysis
2 - Minor Involvement
3 - Significant Dj r> ability
4 - Severely Lisabled (bed, wheelchair, extensive bracing)
Key for Virus and Antibody Studies: 0 - Negative Test
--  Test not Done
- Test in Progress
Virus character was determined by the modified Wecker and McBride tests. 1
1 Considered compatible with vaccine-induced disease were those cases clinically 
indistinguishable from poliomyelitis with some significant residual paralysis 
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